Clinical trial · Interventional
A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma
Phase I Open Label Ascending Dose Study to Assess the Feasibility and Safety of Intermittent Infusions of MTX110 Administered by Convection-Enhanced Delivery (CED) in Patients With Recurrent Glioblastoma (rGBM) (MAGIC-G1)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Strategic decision
Summary
Brief summary (as posted)
A study designed to assess the safety of MTX110 in patients suffering with recurrent glioblastoma. MTX110 will be administered directly to the site of the tumour via a catheter which is inserted during a surgical procedure at the beginning of the study.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Recurrent Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MTX110 | Drug | — | UNRESOLVED |
| Programmable pump and catheter system | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Cohort A: MTX-110
- description
- Weekly dosing of MTX110 via CED until progression/ unacceptable toxicity.
- interventionNames
- Drug: MTX110
- Device: Programmable pump and catheter system
- type
- EXPERIMENTAL
- label
- Cohort B: MTX-110 with optional catheter repositioning
- description
- Weekly dosing of MTX110 via CED until progression. At progression, optional catheter repositioning may occur, followed by continued weekly dosing of MTX110 until next progression/ unacceptable toxicity.
- interventionNames
- Drug: MTX110
- Device: Programmable pump and catheter system
Primary outcomes (2)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Recurrent glioblastoma. * Patients must be healthy enough to tolerate surgery and general anesthesia. * Estimated life expectancy of greater than 3 months. Exclusion Criteria: * Patients scheduled to undergo or are undergoing re-irradiation for the recurrent tumour. * Patients with a history of glioblastoma treatment with carmustine or Gliadel® wafers. * Patients who cannot undergo MRI. * Patients may not have received chemotherapy or bevacizumab ≤ 4 weeks, or metronomic dosed chemotherapy such as daily etoposide or cyclophosphamide (1 week) prior to starting the study drug. * Patients may not have received treatment with tumor treating fields ≤ 1 week prior to starting the study drug. * Patients may not be less than 12 weeks from completion of radiation therapy for the primary tumor. * Patients with neoplastic lesions in the brainstem, cerebellum, or spinal cord; radiological evidence of active; multifocal disease; extensive subependymal disease (tumor touching subependymal space is allowed); tumor crossing the midline or leptomeningeal disease. * Posterior fossa location of the tumor, regardless of its morphology. * Prior, unrelated malignancy requiring current active treatment with the exception of cervical carcinoma in situ and adequately treated basal cell or squamous cell carcinoma of the skin (treatment with tamoxifen or aromatase inhibitors or other hormonal therapy that may be indicated in prevention of prior cancer disease recurrence, are not considered current active treatment).
References
Publications (0)
Data not yet available